InspireMD, Inc. NSPR
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-10.12
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.0M | -$48.8M | $2.6M | -$36.8M | $55.2M |
| 2024 | $7.0M | -$32.0M | $1.5M | -$23.3M | $36.1M |
| 2023 | $6.2M | -$19.9M | $1.8M | -$16.8M | $39.5M |
| 2022 | $5.2M | -$18.5M | $1.1M | -$16.0M | $17.4M |
| 2021 | $4.5M | -$14.9M | $754,000 | -$13.6M | $33.5M |
| 2020 | $2.5M | -$10.5M | $83,000 | -$9.2M | $12.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.12 (distress)
- Working capital / assets 0.731
- Retained earnings / assets -4.356
- EBIT / assets -0.715
- Equity / liabilities 3.887
Source: SEC EDGAR filings · CIK 0001433607 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.